BeiGene’s Tevimbra Recommended for EU Approval in Small Cell Lung Cancer
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist proposing to rename...
Otsuka Files FDA Application for Sibeprenlimab in IgAN Treatment
Japan-based Otsuka Pharmaceutical Co., Ltd. announced the filing of a Biologics License Application (BLA) with...
Basecare Medical Reports 44% Revenue Growth in 2024 IVF Sector
China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has released its 2024 performance...
UCB’s Rystiggo Approved in China for Generalized Myasthenia Gravis
Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from China‘’s National...
Renji Hospital Partners with Raffles Medical Group to Boost Shanghai’s Medical Tourism
Renji Hospital, a comprehensive Class 3A hospital established in 1844 in Shanghai, has partnered with...
AstraZeneca and Daiichi Sankyo Initiate DESTINY-Gastric05 Study for Enhertu in Metastatic Gastric Cancer
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the first patient dosing in...
China Proposes New Measures to Optimize High-End Medical Device Regulation
The National Medical Products Administration (NMPA) has released the “Measures for Optimizing Full Lifecycle Supervision...
GE Healthcare Takes Full Ownership of Japan’s Nihon Medi-Physics
US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...
Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Rheumatoid Arthritis in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
Chinese Firms Nanjing F&S and Hunan Huize Form Alliance for Full-Process Pharma Services
Chinese companies Nanjing F&S Pharmatech Co., Ltd and Hunan Huize Biopharmaceutical Technology Co., Ltd, a...
Huapont Life Sciences Gains NMPA Approval for Generic Daivobet
China-based Huapont Life Sciences Co., Ltd (SHE: 002004) announced that it has received marketing approval...
Chinese IVD Firm Annoroad Gene Targets Global Expansion with IPO
China-based Annoroad Gene Technology (Beijing) Co., Ltd. has submitted an initial public offering (IPO) filing...
Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study...
Abbisko Therapeutics Secures $85M from Merck for Pimicotinib Global Rights
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its German partner Merck KGaA...
Chia Tai Tianqing Launches NPP for Urgent Cancer Treatment in Hong Kong
China-based Chia Tai Tianqing Pharmaceutical has entered into a Named Patient Program (NPP) collaboration with...
Innovent Biologics’ IBI363 Granted Breakthrough Therapy Designation for Melanoma
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received breakthrough therapy designation (BTD)...
NHC Data Reveals Digital Leap for Class 3 Hospitals Amid Drug Cost Crackdown
China’s 2,168 Class 3 public hospitals demonstrated enhanced fiscal discipline in 2023, with medical services...
Hengrui’s HRS-5965 Granted Breakthrough Therapy Designation for IgA Nephropathy
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received breakthrough therapy...
Sanofi’s Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received approval from Japan’s Ministry of...
Pacific Shuanglin Bio-pharmacy Partners with XtalPi for Blood Product Innovation
China-based Pacific Shuanglin Bio-pharmacy Co., Ltd (SHE: 000403) has formed a strategic partnership with Shenzhen-based...